TRCT
ZYBT

Tower Research Capital (TRC)’s Zhengye Biotechnology Holding ZYBT Stock Holding History

Tower Research Capital (TRC)’s Portfolio ZYBT Stock Details ZYBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,912
Closed -$4.59K – 5765
2026
Q1 		$4.59K Buy
4,912
+2,705
+123% +$2.53K ﹤0.01% 4181
2025
Q4 		$2.54K Sell
2,207
-2,255
-51% -$5K ﹤0.01% 4507
2025
Q3 		$11.7K Buy
4,462
+1,126
+34% +$7.8K ﹤0.01% 3859
2025
Q2 		$19.9K Buy
3,336
+3,335
+333,500% +$26.5K ﹤0.01% 3681
2025
Q1 		$5 Buy
+1
New +$5 ﹤0.01% 5116

Other funds holding ZYBT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Tower Research Capital (TRC)'s ZYBT Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Zhengye Biotechnology Holding (ZYBT) in Q2 2026, closing a stake of 4,912 shares — an estimated $4.59K sold.

Tower Research Capital (TRC) first reported a position in ZYBT in Q1 2025 and held it in 5 quarters. The position peaked at $19.9K in Q2 2025. 6 funds tracked by Wall St. Rank hold ZYBT as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Zhengye Biotechnology Holding position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 4,912 Zhengye Biotechnology Holding shares in Q2 2026, an estimated $4.59K.
  • Tower Research Capital (TRC) first reported a position in Zhengye Biotechnology Holding in Q1 2025 and held it in 5 quarters.
  • Tower Research Capital (TRC)'s Zhengye Biotechnology Holding position peaked at $19.9K in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Zhengye Biotechnology Holding as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.